Testosterone replacement therapy (TRT) is a widely used treatment for men with symptomatic hypogonadism. The benefits seen with TRT, such as increased libido and energy level, beneficial effects on bone density, strength and muscle as well as cardioprotective effects, have been well-documented. TRT is contraindicated in men with untreated prostate and breast cancer. Men on TRT should be monitored for side-effects such as polycythemia, peripheral edema, cardiac and hepatic dysfunction.

**Key words**: Hypogonadism, side-effects, testosterone replacement therapy

INTRODUCTION

Testosterone has many beneficial effects, including increasing bone strength and density, inducing hematopoiesis, driving sexual function and libido, providing a cardioprotective effect and increasing muscle strength.[1] Testosterone levels are known to decline as men age. The Baltimore Longitudinal Study of Aging reported the incidence of hypogonadism as 20% in men over 60 years of age, 30% in men over 70 years and 50% in men over 80 years of age.[2]

As men age, a decline in testicular production of testosterone are seen, as well as an increase in sex hormone binding globulin, both of which act to decrease bioavailable testosterone.[3] With this gradual decline, the beneficial effects of testosterone could be diminished and negatively affect physical and emotional well-being. Testosterone replacement therapy (TRT) is a reasonable treatment option often discussed for men with low testosterone levels and symptoms of hypogonadism. When replaced, many of the positive effects of testosterone are regained.[4]

These positive results have led to a drastic increase in the use of testosterone replacement for men with symptomatic hypogonadism, though long-term data is lacking on the safety.

While the beneficial effects of testosterone are rarely disputed and widely publicized, there is a paucity of the literature on the risks of testosterone use. Any man who has a comorbidity that precludes TRT should be informed of all risks. Factors such as exacerbation of prostate cancer, male breast cancer, worsening benign prostatic hyperplasia (BPH), polycythemia and an increased risk of obstructive sleep apnea (OSA) should be considered when administering TRT to a patient. The goal of this review is to highlight the risks and summarize the current literature on safety of TRT.

EFFECT OF TRT ON BPH

One of the major risk factors associated with the administration of testosterone supplementation is its effect on the prostate. We know the prostate to be an androgen-dependent gland and conversely, anti-androgen agents can decrease prostate volume in patients with BPH. As the population continues to age, both the incidence of BPH and late-onset male hypogonadism will continue to rise and practitioners will need to be comfortable with counseling men on the effect of TRT on the prostate.[5]

In a landmark randomized, double-blind, placebo-controlled trial of 44 hypogonadal men, Marks et al. showed that TRT for 6 months improves serum androgen levels, but had little effect on prostate tissue androgen levels, tissue biomarkers and/or gene expression.[6] Testosterone supplementation has been shown to increase prostate size by 12%,[7] but lower urinary tract symptoms (LUTS) and urinary retention do
not worsen in men on testosterone therapy.\cite{8,9} Similarly, the presence of hypogonadism in 312 men with reportable LUTS was not predictive of worsening International Prostate Symptom Scores (IPSS) or maximal urinary flow rates.\cite{10}

In fact, some series report an improvement in LUTS after 1 year of TRT.\cite{11,12} In the most recent, randomized controlled trial, 52 men were randomly assigned to receive TRT. At 1 year, the 23 men randomized to 250 mg of testosterone enanthate every 4 weeks reported significant improvements in IPSS and maximal urinary flow rates compared with baseline and controls.\cite{12} At no point in this trial did any patient require additional medication or suffer urinary retention.

While older men on testosterone therapy do have an increase in overall prostate size, this increase in size does not differ from the increase in prostatic hypertrophy seen in elderly men not on testosterone therapy.\cite{13} Taken together, TRT does not appear to grossly worsen LUTS and is not contraindicated in men diagnosed with BPH.

**EFFECT OF TRT ON PROSTATE CANCER**

It has been over 60 years since Hodges and Huggins described a relationship between serum testosterone levels and prostate cancer progression.\cite{14} Later in 1982, Fowler and Whitmore reported that exogenous testosterone given to patients with metastatic prostate cancer had worse outcomes.\cite{15} Today androgen deprivation therapy remains a cornerstone of treatment for men with advanced prostate cancer, so it is no surprise that TRT is contraindicated in men with diagnosed prostate cancer, as well as high-risk patients, which includes men with first-degree relatives with prostate cancer and African-Americans who have a prostate-specific antigen (PSA) >3 ng/mL.\cite{14,16}

Recently, there has been a paradigm shift whereby TRT usage has increased despite this potential risk. Many longitudinal studies investigating the relationship of endogenous testosterone levels and subsequent risk of prostate cancer failed to find any association.\cite{17} As such, prostate cancer incidence in men on testosterone therapy is similar to men not on testosterone therapy.\cite{18,19} Similarly, in a 3-year prospective trial, the incidence of prostate cancer was similar among men receiving TRT and controls.\cite{20} In a large meta-analysis of 18 prospective studies that included over 3500 men, there was no association between serum androgen levels and the risk of prostate cancer development.\cite{21} Morgentaler et al. proposed a saturation theory where prostate growth becomes insensitive to changes at normal androgen levels due to saturation of the androgen-receptor; however, there is exponential growth at castrate levels.\cite{22} This theory may explain why testosterone does not directly cause prostate cancer \cite{23} but it has been shown to accelerate the development of prostate cancer.\cite{24,25}

For premalignancy, prostatic intraepithelial neoplasia (PIN) appears to be a risk factor for developing prostate cancer, however this association has been mostly demonstrated for high-grade disease.\cite{26,27} There is a lack of long-term data on the use of TRT in men with PIN. In one study, 12 months after TRT, only one patient out of 20 men with previous PIN developed overt prostate cancer.\cite{28}

For men who have previously undergone definitive treatment for prostate cancer, the usage of TRT is becoming more accepted. TRT does not appear to increase cancer recurrence in hypogonadal men following radical prostatectomy.\cite{29} In the most recent study by Pastuszak et al., the authors retrospectively reviewed a cohort of 103 men who underwent prior radical prostatectomy and were treated with TRT. Despite a significant increase in PSA in men receiving TRT, there were twice as many cancer recurrences in the control group after 36 months of follow-up.\cite{30}

For men with untreated prostate cancer on active surveillance, TRT remains controversial. However, several studies have shown that TRT is not associated with progression of prostate cancer as evidenced by either PSA progression or gleason grade upstaging on repeat biopsy.\cite{31,32} In the most recent study by Morgentaler et al., 13 men with symptomatic hypogonadism and untreated prostate cancer received TRT for a median of 2.5 years and no local prostate cancer progression or distant disease was observed.\cite{33}

While there have been reports of metastatic prostate cancer in older men who are on testosterone therapy,\cite{20} these are mostly anecdotal. Because of this potential risk, practitioners are often reluctant to administer testosterone in patients they believe may be at high risk for prostate cancer or whom they suspect may have the low-grade disease. Men on TRT should have frequent PSA monitoring; any major change in PSA (>1 ng/mL) within the first 3-6 months may reflect the presence of a pre-existing cancer and warrants cessation of therapy.\cite{34} Current guidelines on the frequency of PSA monitoring and role of pre-treatment transrectal ultrasound guided prostate biopsy are lacking.\cite{35} Taken together, there has been consistent rejection that TRT causes development of prostate cancer in men, however administration of TRT for hypogonadal men previously treated for high-risk prostate cancer should be taken with caution.

**BREAST CANCER**

While there is no known physiologic link of testosterone directly to the development of breast cancer, it has been suggested that high levels of testosterone may lead to increased aromatization to an active derivative of estrogen, which ultimately may stimulate breast tissue receptors and increase the risk of male breast cancer.\cite{36}
The role of testosterone in breast cancer development is yet to be fully understood. Currently, several case reports exist and one retrospective review sites an incidence of 11% in 45 men on long term TRT over 10 years. Future prospective studies with longer follow-up will determine if such association between TRT and male breast cancer truly exists.

**INFLUENCE OF TESTOSTERONE ON RED BLOOD CELL COUNT**

Testosterone leads to an increase in hemoglobin by as much as 5-7% through its effect on the production of erythropoietin, which can dramatically improve symptoms of anemia in men.

Studies looking at the occurrence of polycythemia as a negative side-effect in men on testosterone therapy are rare. Despite this, polycythemia is an accepted side-effect of TRT. While testosterone exerts a positive effect in men with baseline anemia, it can lead to polycythemia in over 20% of men treated on TRT. Polycythemia may lead to an increased incidence of vascular events, including stroke, myocardial infarction and deep vein thrombosis with possible pulmonary embolus. While these complications are all possible with polycythemia, their theoretical occurrence has not been demonstrated to occur in men on TRT.

Because of this risk of polycythemia, men undergoing TRT should not only have their complete blood count (CBC) monitored during their therapy, but should also have a baseline CBC drawn before testosterone therapy is initiated. While on testosterone therapy, if the hematocrit (HCT) rises greater than 54%, testosterone therapy should be held until the HCT normalizes. If it is restarted after normalization, it should be performed so at a lower dose with continued careful monitoring.

**RELATIONSHIP BETWEEN OSA AND TRT**

OSA is a risk associated with TRT in men, but its etiology is not particularly well understood. While some studies suggested that there is no association between OSA and TRT, others have demonstrated that OSA occurs in men undergoing TRT and when supplementation is stopped, the OSA resolves.

While no clear link has been established, men on TRT should be counseled on the risk of potential OSA when therapy is started. They should be monitored for increased symptoms, such as snoring while sleeping or fatigue. If patients starting TRT already carry a diagnosis of OSA, physicians should counsel these patients that TRT may worsen their symptoms. While, OSA remains to be a relative contraindication to initiation of TRT, more research needs to be completed on this association in order to gain a better understanding of its etiology if there is one at all.

**SYSTEMIC EFFECTS OF TESTOSTERONE**

The systemic effects of TRT may be exacerbated in men with limited cardiovascular reserve. Previous dogma held that androgens could have atherogenic potential. In a randomized, placebo-controlled trial, Basaria et al. reported an increased risk of cardiovascular events in men randomized to TRT; however, this small cohort had a high prevalence of chronic disease. Today, current literature suggests that TRT has a neutral to beneficial effect on reported cardiovascular events. Because some men may have a limited cardiovascular capacity, clinicians prescribing TRT must be cautious with respect to its ability to cause edema.

Until date, no longitudinal studies examine the impact of TRT on the cardiovascular system, however some studies suggest that TRT may serve as an adjunct rehabilitative therapy in patients with congestive heart failure (CHF). While topical testosterone delivery systems avoid first-pass hepatic metabolism, there remains concern regarding TRT in patients with chronic liver disease. The majority of reports of liver toxicity and jaundice are limited to orally-administered alkylated forms of testosterone.

However, a small prospective study representing a cohort of cirrhotic patients demonstrated topical gels to be safe and efficacious. It has also been shown that TRT may improve hepatic function in patients with end-stage liver disease. Because of these mixed results, clinicians should be aware of the possible risks associated with TRT in men with hepatic dysfunction and counsel these men accordingly.

Because TRT is known to cause water retention, caution with testosterone use in patients with chronic renal insufficiency is often advised. In patients with end-stage renal disease (ESRD) on dialysis, fluid shifts are less of a concern in patients on TRT since the fluid retention can be handled with dialysis. While polycythemia may be an adverse side-effect, this is a potential benefit in patients with chronic renal failure and anemia. Furthermore, the half-life of testosterone elimination after withdrawal appears similar between patients with and without ESRD. Few studies have assessed the effects of TRT in patients with chronic kidney disease; however, small studies have suggested that TRT has anabolic effects among ESRD patients, even in the absence of hypogonadism. Aside from frequent monitoring of congestive symptoms and peripheral edema in this select population, TRT appears to be safe for patients with chronic kidney disease without dose adjustment.

When testosterone reaches supra-therapeutic levels, aggressive behavior and increased rates of suicide among adolescent users have been reported; however, no study has documented a negative impact on cognition in men patients.
receiving TRT. In fact, studies have shown that testosterone replacement to eugonadal levels may improve or stabilize cognitive function. Lower levels of testosterone have a negative impact on spatial and verbal abilities, as well as cognitive function; therefore, it is no surprise that normalizing testosterone levels results in cognitive improvements.

With exogenous testosterone supplementation, the pulsatile release of gonadotropin-releasing hormone is blunted and the release of follicle-stimulating hormone and luteinizing hormone are depressed. As such, a decrease in spermatogenesis is seen. While this effect may not be of importance to many men who have completed their families, physicians prescribing TRT need to be aware.

When serum levels of testosterone are increased, a concurrent increase in the secretion of sebum occurs, which can lead to acne. Despite this known association, this effect is typically minimal. Case reports regarding testosterone supplementation leading to changes in hair patterns have been documented; however no randomized, placebo-controlled trials exist. Various topical and intramuscular injectable forms of testosterone are associated with a variety of skin reactions, mainly erythema and pruritus in up to 60% of users.

**EFFECTS OF TESTOSTERONE ON BODY HABITUS**

TRT is associated with external, physical changes in the men. Exogenous testosterone is known to cause an imbalance in the hypothalamic-pituitary axis. As such, testosterone can be converted to estrogen by aromatization. Excess estrogens may lead to gynecomastia and/or breast pain, both of which may be seen in 10–25% of men on TRT. The ratio of estradiol to androgens is the key factor in the development of gynecomastia rather than absolute increases in androgens themselves. Clinicians must be aware of non-iatrogenic causes of gynecomastia and therefore the appropriate work-up should be sought out to rule out other pathology, especially if there is any breast tenderness or unilateral gynecomastia. Only a few case-reports describe a relationship between male breast cancer and TRT.

In addition, excess estrogens may cause an increase in visceral obesity. With vigilant monitoring of serum estrogen levels, TRT has been shown to promote weight loss. Well-known to many prescribers of TRT is a risk of water retention and/or edema. The etiology of this association remains unclear to date. The degree of retention is generally mild. As mentioned above, men on TRT with a history of CHF should follow closely.

**CONCLUSIONS**

TRT has numerous benefits that can great enhance a patient’s quality-of-life. Before prescribing TRT, one must be conscientious of its adverse effects. Data on the safety of TRT specific to our aging population is not currently available; however TRT has been linked to prostate cancer, BPH, polycythemia and OSA. A full assessment of the morbidity of TRT would require a large-scale, randomized, controlled trial. To date, physicians remain in a quandary about the best approach to care for men with symptoms of hypogonadism. TRT, when given to appropriately selected patients with vigilant monitoring as outlined in this review and in Table 1, can bring improvements in quality-of-life, energy level, libido, muscle mass, cognition and bone density.

**Table 1: Potential risks of TRT and associated monitoring strategies**

| Potential risk                | Suggested monitoring strategies                                                                 |
|-------------------------------|--------------------------------------------------------------------------------------------------|
| Cardiovascular disease        | Baseline blood pressure checks and repeats at 3 and 6 months, then annually thereafter. For high-risk patients, consider cardiology referral |
| Erythrocytosis                | Obtain baseline HCT then at 3 and 6 months, then annually thereafter. If HCT is >54%, stop TRT and restart at lower dose |
| Fluid retention               | Patient history and physical exam. Stop TRT if CHF is uncontrolled                               |
| BPH                           | Patient questionnaire and history. Refer to urologist if: IPSS+above 19 and stop TRT               |
| Prostate cancer               | Obtain baseline DRE* and serum PSA then again at 3 and 6 months. Continual monitoring depending on the patient’s race/age. Refer to urologist if PSA rises over 4 ng/mL. Abnormal DRE |
| Acne                          | Patient history and physical exam. Dose adjustment and/or referral to dermatology                |
| Hepatotoxicity                | Patient history and physical exam. Liver function tests are unnecessary in gel, pellet and IM preparations |
| Infertility                   | Patient history and physical exam. Reconsider alternative strategies if patient desires to father children |
| OSA                           | Baseline patient history and physical exam and again between 3 and 6 months. Consider alternate causes of OSA |
| Gynecomastia/breast cancer    | Exclude other etiologies with patient history and physical exam. Review all medications. Complete hormone evaluation may be necessary. Medications implicated to cause gynecomastia: Anti-androgens-finasteride, bicalutamide Antibiotics-isoniazid, ketoconazole, metronidazole Antihypertensives-amlopidine, captopril, diltiazem, verapamil, nifedipine Gl agents-cimetidine, omeprazole Psychiatric-diazepam, haloperidol, tricyclic antidepressants |

TRT=Testosterone replacement therapy, HCT=Hematocrit, BPH=Benign prostatic hyperplasia, DRE=Digital rectal examination, CHF=Congestive heart failure, IPSS=International prostate symptom score, PSA=Prostate-specific antigen, IM=Intramuscular, OSA=Obstructive sleep apnea, GI=Gastrointestinal, Digital rectal examination, International prostate symptom score
REFERENCES

1. Gruenewald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 2003;51:101-15.

2. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab 2001;86:724-31.

3. Basaria S, Dobs AS. Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 1999;15:131-42.

4. Surampudi PN, Wang C, Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int J Endocrinol 2012;2012:1-52.

5. Shigehara K, Namiki M. Late-onset hypogonadism syndrome and lower urinary tract symptoms. Korean J Urol 2011;52:657-63.

6. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: A randomized controlled trial. JAMA 2006;296:2351-61.

7. Holmäng S, Mårin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993;23:99-106.

8. Sib R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661-7.

9. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. Am J Geriatr Soc 2010;58:1134-43.

10. Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, et al. Endocrine status in elderly men with lower urinary tract symptoms: Correlation of age, hormonal status, and lower urinary tract function. The prostate study group of the Austrian society of urology. Urology 2000;55:397-402.

11. Ko YH, Moon du G, Moon KH. Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: One year follow-up. World J Mens Health 2013;31:47-52.

12. Shigehara K, Sugimoto K, Konaka H, Iijima M, Fukushima M, Maeda Y, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: A randomised controlled study. Aging Male 2011;14:53-8.

13. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994;40:341-9.

14. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-40.

15. Fowler JE Jr, Whitmore WF Jr. Considerations for the use of testosterone with systemic chemotherapy in prostate cancer. Cancer 1982;49:1373-7.

16. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59.

17. Morgentaler A. Testosterone therapy for men at risk for or with history of prostate cancer. Curr Treat Options Oncol 2006;7:363-9.

18. Singh AB, Hsia S, Alaupovic P, Sinha-Hikim I, Woodhouse L, Buchanan TA, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002;87:136-43.

19. Snyder PJ, Peachey H, Berlin JA, Hannoush P, Haddad G, Dlewati A, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85:2670-7.

20. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482-92.

21. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83.

22. Morgentaler A, Triash AM. Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-20.

23. Heikkilä R, Aho K, Heliövaara M, Hakama M, Marniemi J, Reunanen A, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: A longitudinal study. Cancer 1999;86:312-5.

24. Ramasamy R, Fisher ES, Schlegel PN. Testosterone replacement and prostate cancer. Indian J Urol 2012;28:123-8.

25. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992;75:1092-8.

26. Akhavan A, Keith JD, Bastacky SI, Cai C, Wang Y, Nelson JB. The proportion of cores with high-grade prostate intraepithelial neoplasia on extended-pattern needle biopsy is significantly associated with prostate cancer on site-directed repeat biopsy. BJU Int 2007;99:765-9.

27. Schoenfeld L, Jones JS, Zippe CD, Reuther AM, Klein E, Zhou M, et al. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glandular suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. BJU Int 2007;99:770-4.

28. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: Results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003;170:2348-51.

29. Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int 2010;105:1397-401.

30. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathymaoryth K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol 2013; Impress.

31. Morgentaler A. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer. J Sex Med 2009;6:574-7.

32. Morgentaler A. Testosterone therapy in men with prostate cancer: Scientific and ethical considerations. J Urol 2013;189 Suppl 1:S26-33.

33. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol 2011;185:1256-60.

34. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for a standardized monitoring plan. J Androl 2003;24:299-311.

35. Practice Committee of the American Society for Reproductive Medicine. Treatment of androgen deficiency in the aging male. Fertil Steril 2004;81:1437-40.

36. Kenemans P, van der Mooren MJ. Androgens and breast cancer risk. Endocrinol 2011;14:53-8.

37. Practice Committee of the American Society for Reproductive Medicine. Testosterone therapy in men with androgen deficiency syndrome: Scientific and ethical considerations. J Urol 2013;189 Suppl 1:S26-33.

38. Thomas SR, Evans PJ, Holland PA, Biswas M, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166:1483-9.

39. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Breast cancer risk and use of hormone therapy in case-control study of postmenopausal women. Breast Cancer Res Treat 2006;96:263-5.
40. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1973;289:72-80.
41. Shahani S, Braga-Basaria M, Maggio M, Basaria S. Androgens and erythropoiesis: Past and present. J Endocrinol Invest 2009;32:704-16.
42. Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995;43:899-901.
43. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: A meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005;60:1451-7.
44. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-72.
45. Cistulli PA, Grunstein RR, Sullivan CE. Effect of testosterone administration on upper airway collapsibility during sleep. Am J Respir Crit Care Med 1994;150:530-2.
46. Basaria S, Coviolesi AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363:109-22.
47. Mathur A, Malkin C, Saeed B, Muthusamy R, Jones TH, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol 2009;161:443-9.
48. Nam UH, Wang M, Crisostomo PR, Markel TA, Lahm T, Meldrum KK, et al. The effect of chronic exogenous androgen on myocardial function following acute ischemia-reperfusion in hosts with different baseline levels of sex steroids. J Surg Res 2007;142:113-8.
49. Chahla EJ, Hayek ME, Morley JE. Testosterone replacement therapy and cardiovascular risk factors modification. Aging Male 2011;14:83-90.
50. Saxton JM, Zwierska I, Mathur A, Channer KS. Study protocol to investigate the effects of testosterone therapy as an adjunct to exercise rehabilitation in hypogonadal males with chronic heart failure. BMC Cardiovasc Disord 2006;6:46.
51. Einbeck D. Meta-analysis confirms positive effect. Testosterone substitution in heart failure? MMW Fortschr Med 2012;154:83.
52. Kang NN, Fu L, Xu J, Han Y, Cao JX, Sun JF, et al. Testosterone improves cardiac function and alters angiotensin II receptors in isoproterenol-induced heart failure. Arch Cardiovasc Dis 2012;105:68-76.
53. Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet 1977;2:262-3.
54. Yurci A, Yucesoy M, Unluhizarci K, Toran E, Gursoy S, Baskol M, et al. Effects of testosterone gel treatment in hypogonadal men with liver cirrhosis. Clin Res Hepatol Gastroenterol 2011;35:845-54.
55. Neff GW, O’Brien CB, Montalbano M, Meyer D, DeManno A, Mushu H, et al. Beneficial effects of topical testosterone replacement in patients with end-stage liver disease. Dig Dis Sci 2004;49:1186-9.
56. Johansen KL. Testosterone metabolism and replacement therapy in patients with end-stage renal disease. Semin Dial 2004;17:202-8.
57. Johansen KL. Treatment of hypogonadism in men with chronic kidney disease. Adv Chronic Kidney Dis 2004;11:348-56.
58. Trenton AJ, Currier GW. Behavioural manifestations of anabolic steroid use. CNS Drugs 2005;19:571-95.
59. Janowsky JS. Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci 2000;12:407-14.
60. Beaucet O. Testosterone and cognitive function: Current clinical evidence of a relationship. Eur J Endocrinol 2006;155:773-81.
61. Fuller SJ, Tan RS, Martins RN. Androgens in the etiology of Alzheimer’s disease in aging men and possible therapeutic interventions. J Alzheimers Dis 2007;12:129-42.
62. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab 2002;87:5001-7.
63. Thilers PP, Macdonald SW, Herlitz A. The association between endogenous free testosterone and cognitive performance: A population-based study in 35 to 90 year-old men and women. Psychoneuroendocrinology 2006;31:565-76.
64. Mmars N, Hayes V, Welch S, Rini A, Helgeson C, Dokler M, et al. Testosterone deficiency in young men: Marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998;83:1866-92.
65. Kurokawa I, Danby FW, Ju Q, Wang X, Xiang LF, Xia L, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009;18:821-32.
66. Eckman A, Dobs A. Drug-induced gynecomastia. Expert Opin Drug Saf 2008;7:691-702.
67. Schwarz ER, Willix RD Jr. Impact of a physician-supervised exercise-nutrition program with testosterone substitution in partial androgen-deficient middle-aged obese men. J Geriatr Cardiol 2011;8:201-6.
68. Tan KS, Salazar JA. Risks of testosterone replacement therapy in ageing men. Expert Opin Drug Saf 2004;3:599-606.
69. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-39.

How to cite this article: Osterberg EC, Bernie AM, Ramasamy R. Risks of testosterone replacement therapy in men. Indian J Urol 2014;30:2-7.

Source of Support: Nil, Conflict of Interest: None declared.